This HTML5 document contains 109 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n19http://www.rxlist.com/cgi/generic3/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00958/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n28http://linked.opendata.cz/resource/AHFS/
n15http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00958/identifier/national-drug-code-directory/
n5http://linked.opendata.cz/resource/drugbank/dosage/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00958/identifier/chemspider/
n12http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB00958/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00958/identifier/pharmgkb/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00958/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n29http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00958/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00958/identifier/kegg-drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00958/identifier/pubchem-substance/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00958
rdf:type
n3:Drug
n3:description
An organoplatinum compound that possesses antineoplastic activity. [PubChem]
n3:dosage
n5:271B434B-363D-11E5-9242-09173F13E4C5 n5:271B434C-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Natarajan G, Malathi R, Holler E: Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem Pharmacol. 1999 Nov 15;58(10):1625-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10535754 # Knox RJ, Friedlos F, Lydall DA, Roberts JJ: Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 1986 Apr;46(4 Pt 2):1972-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3512077 # Canetta R, Rozencweig M, Carter SK: Carboplatin: the clinical spectrum to date. Cancer Treat Rev. 1985 Sep;12 Suppl A:125-36. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3002623
n3:group
approved
n3:halfLife
Initial plasma half-life (alpha) = 1.1 to 2 hours; Post distribution plasma half-life (beta) = 2.6 - 5.9 hours.
n3:indication
For the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of PARAPLATIN and cyclophosphamide. It is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.
n3:manufacturer
n4:271B4343-363D-11E5-9242-09173F13E4C5 n4:271B4344-363D-11E5-9242-09173F13E4C5 n4:271B4341-363D-11E5-9242-09173F13E4C5 n4:271B4342-363D-11E5-9242-09173F13E4C5 n4:271B4334-363D-11E5-9242-09173F13E4C5 n4:271B4335-363D-11E5-9242-09173F13E4C5 n4:271B4333-363D-11E5-9242-09173F13E4C5 n4:271B433F-363D-11E5-9242-09173F13E4C5 n4:271B4340-363D-11E5-9242-09173F13E4C5 n4:271B4336-363D-11E5-9242-09173F13E4C5 n4:271B433E-363D-11E5-9242-09173F13E4C5 n4:271B4339-363D-11E5-9242-09173F13E4C5 n4:271B433A-363D-11E5-9242-09173F13E4C5 n4:271B4337-363D-11E5-9242-09173F13E4C5 n4:271B4338-363D-11E5-9242-09173F13E4C5 n4:271B433B-363D-11E5-9242-09173F13E4C5 n4:271B4332-363D-11E5-9242-09173F13E4C5 n4:271B433D-363D-11E5-9242-09173F13E4C5 n4:271B433C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00958 n12:DB00958
dcterms:title
Carboplatin
adms:identifier
n17:31355 n20:D01363 n21:436073 n22:DB00958 n23:38904 n24:46507170 n25:0703-3249-11 n26:PA448803 n27:Carboplatin
n3:mechanismOfAction
Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.
n3:packager
n4:271B432A-363D-11E5-9242-09173F13E4C5 n4:271B4323-363D-11E5-9242-09173F13E4C5 n4:271B4324-363D-11E5-9242-09173F13E4C5 n4:271B4321-363D-11E5-9242-09173F13E4C5 n4:271B4322-363D-11E5-9242-09173F13E4C5 n4:271B431F-363D-11E5-9242-09173F13E4C5 n4:271B4320-363D-11E5-9242-09173F13E4C5 n4:271B4331-363D-11E5-9242-09173F13E4C5 n4:271B432F-363D-11E5-9242-09173F13E4C5 n4:271B4330-363D-11E5-9242-09173F13E4C5 n4:271B432D-363D-11E5-9242-09173F13E4C5 n4:271B432E-363D-11E5-9242-09173F13E4C5 n4:271B432B-363D-11E5-9242-09173F13E4C5 n4:271B432C-363D-11E5-9242-09173F13E4C5 n4:271B4329-363D-11E5-9242-09173F13E4C5 n4:271B4327-363D-11E5-9242-09173F13E4C5 n4:271B4328-363D-11E5-9242-09173F13E4C5 n4:271B4325-363D-11E5-9242-09173F13E4C5 n4:271B4326-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
The major route of elimination of carboplatin is renal excretion. After 24 hours, all of the platinum is recovered in the urine as carboplatin. Whether biliary excretion occurs is not known.
n3:synonym
Paraplatin cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) Carboplatin cis-Diammine(1,1-cyclobutanedicarboxylato)platinum cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii) CBDCA
n3:toxicity
Toxic by ingestion. May be create toxic effect through inhalation or skin contact. May cause reproductive defects. May act as a sensitizer. ORL-RAT LD<sub>50</sub> 343 mg kg-1; SCN-RAT LD<sub>50</sub> 72 mg kg-1; IPN-MUS LD<sub>50</sub> 118 mg kg-1
n3:volumeOfDistribution
* 16 L [apparent volume of distribution, 30 minute IV infusion of 300 mg/m^2 to 500 mg/m^2]
n10:hasAHFSCode
n28:10-00-00
n3:foodInteraction
Avoid echinacea as it may decrease effectiveness of immunosuppresants like carboplatin
n3:proteinBinding
Carboplatin is not bound to plasma protein. However, the platinum itself from carboplatin irreversibly binds to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
n3:synthesisReference
Jingzun Wang, Huisheng Qu, Lei Wang, Ting Wang, "Supermolecular carboplatin derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions." U.S. Patent US07259270, issued August 21, 2007.
n14:hasConcept
n15:M0024707
foaf:page
n19:carboplat.htm n29:carboplatin.html
n3:IUPAC-Name
n6:271B434E-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B4354-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B4353-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B4350-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B4351-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B4352-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B434D-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:L01XA02
n3:H-Bond-Acceptor-Count
n6:271B435A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B435B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B4355-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B4356-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B4358-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B4357-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B4359-363D-11E5-9242-09173F13E4C5
n3:absorption
The Cmax values and areas under the plasma concentration versus time curves from 0 to infinity (AUC inf) increase linearly with dose, although the increase was slightly more than dose proportional. Carboplatin exhibits linear pharmacokinetics.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
41575-94-4
n3:category
n3:clearance
* 4.4 L/hour [total body clearance, 30 minute IV infusion of 300 mg/m^2 to 500 mg/m^2]
n3:containedIn
n13:271B4346-363D-11E5-9242-09173F13E4C5 n13:271B4347-363D-11E5-9242-09173F13E4C5 n13:271B4345-363D-11E5-9242-09173F13E4C5 n13:271B434A-363D-11E5-9242-09173F13E4C5 n13:271B4348-363D-11E5-9242-09173F13E4C5 n13:271B4349-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B435F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B4361-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B4362-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B435E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B435D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B4360-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B434F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B435C-363D-11E5-9242-09173F13E4C5